HVSEN Biotechnology Hits Day Low of CNY 21.51 Amid Price Pressure

HVSEN Biotechnology Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock dropping by 8.84% on July 17, 2026. The stock reached an intraday low of CNY 21.51, reflecting a challenging trading session. In terms of performance metrics, HVSEN's one-day performance contrasts with the China Shanghai Composite, which fell by 3.05%. Over the past week, HVSEN has seen a decrease of 4.73%, while the broader index declined by 5.81%. On a monthly basis, the stock is down 5.61%, compared to the composite's 8.37% drop. Despite the recent downturn, HVSEN has shown resilience over the past year, with a slight decline of 0.14%, while the Shanghai Composite has gained 7.03%. Year-to-date, HVSEN has performed positively, up 3.91%, in contrast to the composite's negative performance of 5.16%. The company has reported strong operational metrics, including a notable increase in profits and a high return on equity of 13.37%. However, the long-term growth outlook remains a point of consideration, with net sales and operating profit growing at annual rates of 12.73% and 9.34%, respectively, over the last five years.